Michael W. Scherz

Promotion of sleep by targeting the orexin system in rats, dogs and humans

Catherine Brisbare‐Roch, Jasper Dingemanse, Ralf Koberstein et al. · Nature Medicine · 2007 · 567 citations

Life Sciences, Neurobiology, Neuroscience +12

2-Imino-thiazolidin-4-one Derivatives as Potent, Orally Active S1P₁Receptor Agonists

Martin H. Bolli, Stefan Abele, Christoph A. Binkert et al. · Journal of Medicinal Chemistry · 2010 · 178 citations · Full text

Medicine, Immunology, Pharmacology +17

Pharmacology of the Urotensin-II Receptor Antagonist Palosuran (ACT-058362; 1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea Sulfate Salt): First Demonstration of a Pathophysiological Role of the Urotensin System

Martine Clozel, Christoph A. Binkert, Magdalena Birker et al. · Journal of Pharmacology and Experimental Therapeutics · 2004 · 132 citations · Full text

Medicine, Pharmacology, Molecular Pharmacology +12

Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P₁receptor modulator: Favorable impact of dose up-titration

Patrick Brossard, Michael W. Scherz, Atef Halabi et al. · The Journal of Clinical Pharmacology · 2014 · 65 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

UROTENSIN II MEDIATES ERK1/2 PHOSPHORYLATION AND PROLIFERATION IN GPR14-TRANSFECTED CELL LINES

Patrick Ziltener, Célia Mueller, Bénédicte Haenig et al. · Journal of Receptors and Signal Transduction · 2002 · 56 citations

Life Sciences, Biochemistry, Molecular Biology +16